MetaCap

Annovis Bio Inc. Company Profile

NYSE: ANVSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.7113-0.0371 (-4.96%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Annovis Bio at a glance

Annovis Bio Inc. (NYSE: ANVS) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Malvern, PA. Annovis Bio is led by Dr. Maria L. Maccecchini Ph.D. and employs about 7 people. The company's shares have traded publicly since 2020.

At a market capitalization of $44.1 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001477845, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Annovis Bio do?

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.

Business description based on the company's public filings.

Company information

Legal name
Annovis Bio Inc.
Ticker
NYSE: ANVS
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Maria L. Maccecchini Ph.D.
Employees
7
Headquarters
101 Lindenwood Drive, Malvern, PA, United States
Phone
484 875 3192
IPO year
2020
Market cap
$44.12M
SEC CIK
0001477845
Latest annual report
10-K · Mar 13, 2026

Companies similar to Annovis Bio

ANVS peer companies
CompanyPrice% ChgMarket capCompare
GANXGain Therapeutics Inc.0.9994-4.82%$44.50Mvs ANVS
QUCYQuantum Cyber N.V.0.512-7.25%$44.67Mvs ANVS
RLYBRallybio Corporation15.47-0.32%$43.32Mvs ANVS
SPROSpero Therapeutics Inc.0.742-10.20%$43.23Mvs ANVS
APLMApollomics Inc. Class A15.54-6.92%$45.28Mvs ANVS
RNXTRenovoRx Inc.0.942-10.29%$45.45Mvs ANVS
CRBPCorbus Pharmaceuticals Holdings Inc.2.06-15.40%$42.45Mvs ANVS
HOWLWerewolf Therapeutics Inc.0.9466-3.97%$46.00Mvs ANVS

Related